Tumor-agnostic biomarkers, including tumor mutational burden (TMB-high) (Rizvi et al., 2015)>, mismatch repair status (Marabelle et al., 2020), and PD-L1 expression (Herbst et al., 2016; Kowanetz et al., 2018) have emerged to identify “hot” tumors likely to benefit from anti-PD-1 treatment. This evidence concerns the gene CD274 and neoplasm.